Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions

Radiopharmaceutical therapy (RPT) has, in comparison to external-beam radiation therapy (EBRT), the unique advantage of addressing all tumor sites, including occult metastases. On the other hand, dose heterogeneity is the Achilles heel of RPT. Tumor-absorbed doses can vary widely between patients